Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63)

Veterinary Parasitology

Volumn 60, Issue 3-4, 1995, Pages 199-212

  Olobo, J O ^a   Anjili, C O ^b   Gicheru, M M ^a   Mbati, P A ^b   Kariuki, T M ^a   Githure, J I ^b   Koech, D K ^b   McMaster, W R ^c  

^a INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Leishmania major; Monkey; Vaccination

Indexed keywords

BCG VACCINE; LEISHMANIA VACCINE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; INTRADERMAL DRUG ADMINISTRATION; LEISHMANIA MAJOR; LEISHMANIASIS; MONKEY; NONHUMAN; SERODIAGNOSIS; VACCINATION;

ANIMAL; ANTIBODIES, PROTOZOAN; ANTIBODY SPECIFICITY; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; COMPARATIVE STUDY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTES; METALLOENDOPEPTIDASES; MONKEY DISEASES; MYCOBACTERIUM BOVIS; SUPPORT, NON-U.S. GOV'T; VACCINATION; VACCINES, SYNTHETIC;

ANIMALIA; CERCOCEBUS; CERCOPITHECUS; CERCOPITHECUS AETHIOPS; ESCHERICHIA COLI; LEISHMANIA MAJOR; PHLEBOTOMINAE;

EID: 0028803795     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-4017(95)00788-6     Document Type: Article

References (41)

1. The adjuvant effect of interleukin-12 in a vaccine against Leischmania major
2. Evaluation of optimum dose of culture-derived Leishmania major promastigotes required to assess the immune status of vervet monkeys
3. Isolation of Leishmania major from a naturally infected vervet monkey (Cercopithecus aethiops) in Kiambu District, Kenya
4. Modification of Leishmania gp63 genes by the polymerase chain reaction for expression of nonfusion protein at high levels in Escherichia coli: application to mapping protective T cell determinants
5. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniosis
6. Monoclonal antibody affinity purification of a Leishmania membrane glycoprotein and its inhibition of a Leishmania macrophage binding
7. Effective immunization against cutaneous leishmaniosis with recombinant Bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63
8. Cell-mediated responses of immunized vervet monkeys to defined Leishmania T-cell epitopes
9. The correlation between delayed-type hypersenstivity, lymphocyte activation and protective immunity in experimental murine leishmaniosis
10. Changes in the antigenic profiles of Leishmania parasites following temperature shifts
11. Production of interferon γ in cultures of whole blood obtained in the course of and after healing of cutaneous leishmaniosis
12. The suitability of East African nonhuman primates as animal models for cutaneous leishmaniosis
13. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine cutaneous leishmaniosis
14. Production of interferon γ, interleukin 2, interleukin 4 and interleukin 10 by CD4 + lymphocytes in vivo during healing and progressive murine leishmaniosis
15. Mouse immunoglobulin allotypes: description and special methodology
16. Prophylactic immunisation against experimental leishmaniosis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection
17. Prophylactic immunisation against experimental leishmaniosis. II. Further characterisation of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes
18. Immunoprotective Leishmania major synthetic T cell epitopes
19. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
20. Experimental transmission of Leishmania major to vervet monkeys (Cercophitecus aethiops) by bites of Phlebotomus duboscqi (Diptera, Psychodidae)
21. Distinctive cellular immunity in genetically susceptible BALB/C mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites
22. Leishmaniosis: immunity, immunopathology and immunodiagnosis
23. Experimental visceral leishmaniosis: production of interleukin 2 and interferon γ, tissue immune raction, and response to treatment with interleukin 2 and interferon γ
24. Measurement of serum antibodies against native Leishmania gp63 distinguishes between ongoing and previous L donovani infection
25. Reactivity of some monoclonal antibodies specific for human lymphocytes with vervet monkey peripheral blood mononuclear cells
26. Mitogenic responses of peripheral blood mononuclear cells of vervet monkeys (Cercophitecus aethiops) Apparent role of adherent cells
27. Delayed-type hypersensitivity responses in vervet monkeys self-cured from experimental cutaneous leishmaniosis
28. Antibodies to Leishmania tropica promastigotes during infection in mice of various genotypes
29. IFN-γ and delayed-type hypersensitivity are associated with cutaneous leishmaniosis in vervet monkeys following secondary rechallenge with Leishmania major
30. Selection of a skin test antigen for American Visceral Leishmaniosis
31. Effective immunisation against cutaneous leishmaniosis with defined membrane antigens reconstituted into liposomes
32. The involvement of the major surface glycoprotein gp63 of Leishmania pomastigotes in attachment to macrophages
33. Human T cell responses to gp63, a surface antigen of Leishmania
34. IL-12: initiation cytokine for cell-mediated immunity
35. Immunoregulation of cutaneous leishmaniosis: T cell lines which transfer protective immunity or exacerbation belong to different helper subsets and respond to distinct parasite antigens
36. Antibody responses of visceral leishmaniosis patients to gp63, a major surface glycoprotein of Leishmania species
37. Salivary gland lysates from the sandfly Lutzomyia longipalpis enhance Leishmania infectivity
38. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some applications
39. Enzyme immunoassay for parasitic diseases
40. Oral Salmonella typhimurium (AroA -) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper and protective immunity against leishmaniosis
41. Identification and characterisation of host-protective T-cell epitopes of a major glycoprotein (gp63) from Leishmaniosis major